2024
Personalizing the empiric treatment of gonorrhea using machine learning models
Murray-Watson R, Grad Y, St. Cyr S, Yaesoubi R. Personalizing the empiric treatment of gonorrhea using machine learning models. PLOS Digital Health 2024, 3: e0000549. PMID: 39141668, PMCID: PMC11324139, DOI: 10.1371/journal.pdig.0000549.Peer-Reviewed Original ResearchGonococcal Isolate Surveillance ProjectTreatment of gonorrheaEmpirical treatmentAntimicrobial-resistantNational surveillance systemEffects of first-line therapyEmpirical treatment of gonorrhoeaPrevalence of antimicrobial-resistantPrevalence of resistant strainsStandard guidelinesFirst-line therapyResistant to ciprofloxacinFirst-line antibioticsRecommended first-line antibioticsEmergence of antimicrobial-resistantPatients' basic characteristicsStrains of Neisseria gonorrhoeaeSurveillance projectPrescribing effective treatmentCeftriaxoneGonorrheaRecommended treatmentEffective treatmentPersonalized treatmentCefiximeNet Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty
Yaesoubi R, Kunst N. Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty. Medical Decision Making 2024, 44: 770-786. PMID: 39056310, DOI: 10.1177/0272989x241262343.Peer-Reviewed Original ResearchResults of cost-effectiveness analysesNet monetary benefitCost-effectiveness planeCost-effectiveness analysisMonetary benefitsDecision uncertaintyDecision problemEffect estimatesHypothetical decision problemResults of economic evaluationsValue-of-informationDecision makersCost-effectiveness ratioEconomic evaluation studiesCorrelated costsHigh varianceLevel of uncertaintyParameter uncertaintiesEconomic evaluationMagnitude of parametersMakersDecisionUncertaintyCostMonetaryAssessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyHow many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?
Yaesoubi R. How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses? Value In Health 2024, 27: 1553-1563. PMID: 38977192, DOI: 10.1016/j.jval.2024.06.016.Peer-Reviewed Original ResearchProbabilistic sensitivity analysesIncremental cost-effectiveness ratioProbabilistic cost-effectiveness analysisCost-effectiveness analysisEstimate incremental cost-effectiveness ratiosIncremental cost-effectiveness ratio estimatesCost-effectiveness ratioDecision optionsStochastic modelPresence of parameter uncertaintiesCostParameter uncertaintiesUncertaintyLevel of accuracyInequalitySensitivity analysisEstimationMonteModelMonte Carlo samplingParameter samplesChebyshev inequalityImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-RReply to "Considering Health Systems Worldwide: Point of View From a Middle-Income Country".
Tu L, Melnick E, Venkatesh A, Sheth K, Navaratnam D, Yaesoubi R, Forman H, Mahajan A. Reply to "Considering Health Systems Worldwide: Point of View From a Middle-Income Country". American Journal Of Roentgenology 2024, 222: e2430900. PMID: 38294162, DOI: 10.2214/ajr.24.30900.Peer-Reviewed Original Research
2023
Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness.
Tu L, Melnick E, Venkatesh A, Sheth K, Navaratnam D, Yaesoubi R, Forman H, Mahajan A. Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness. American Journal Of Roentgenology 2023, 222: e2330060. PMID: 37937837, DOI: 10.2214/ajr.23.30060.Peer-Reviewed Original ResearchQuality-adjusted life yearsEvaluation of patientsSecondary prevention measuresEmergency departmentProbabilistic sensitivity analysesConventional MRICumulative quality-adjusted life yearsCost-effective strategyIncremental costNoncontrast CT headAcute stroke treatmentSpecialized MRISelection of patientsHigher quality-adjusted life yearsConventional brain MRIMarkov decision-analytic modelNon-contrast CTNoncontrast head CTHealthcare system perspectiveUse of MRIBase-case analysisPrevention measuresDecision analytic modelGreater quality-adjusted life yearsDeterministic sensitivity analysesThe Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States
Yaesoubi R, Xi Q, Hsu K, Gift T, St. Cyr S, Rönn M, Salomon J, Grad Y. The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States. American Journal Of Epidemiology 2023, 193: 17-25. PMID: 37625444, PMCID: PMC10773484, DOI: 10.1093/aje/kwad175.Peer-Reviewed Original ResearchConceptsRapid drug susceptibility testDrug susceptibility testGonorrhea casesSusceptibility testsFirst-line treatmentBurden of gonorrheaGonococcal infectionGonorrhoea transmissionAntibiotic treatmentPatient outcomesIndividualized treatmentLife spanDrug susceptibilityCare testRapid pointEffective life spanAntibiotic resistanceAntibioticsTest specificityGonorrheaMenCiprofloxacinTreatmentCorrect ascertainmentLong-term impactResistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study
Reichert E, Yaesoubi R, Rönn M, Gift T, Salomon J, Grad Y. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study. The Lancet Microbe 2023, 4: e781-e789. PMID: 37619582, PMCID: PMC10865326, DOI: 10.1016/s2666-5247(23)00145-3.Peer-Reviewed Original ResearchConceptsPrevalence of resistancePrimary outcomeGonococcal infectionGonorrhea treatmentCombination therapyAntibiotic resistanceResistance emergenceNew antibioticsNew drugsUrgent public health concernCombination therapy strategiesSexual activity groupsPopulation-level prevalencePublic health concernSecondary outcomesAnnual incidenceGonorrhoea transmissionCurrent therapiesMSM populationUS CentersMathematical modelling studyCurrent drugsUS populationNeisseria gonorrhoeaeInfectious diseasesCT With CTA Versus MRI in Patients Presenting to the Emergency Department With Dizziness: Analysis Using Propensity Score Matching.
Tu L, Navaratnam D, Melnick E, Forman H, Venkatesh A, Malhotra A, Yaesoubi R, Sureshanand S, Sheth K, Mahajan A. CT With CTA Versus MRI in Patients Presenting to the Emergency Department With Dizziness: Analysis Using Propensity Score Matching. American Journal Of Roentgenology 2023, 221: 836-845. PMID: 37404082, DOI: 10.2214/ajr.23.29617.Peer-Reviewed Original ResearchConceptsSecondary stroke prevention medicationsStroke prevention medicationsEmergency departmentPrevention medicationsEchocardiography evaluationPosterior circulation strokeProportion of patientsGroup of patientsPhysical examination findingsNeuroimaging resultsUse of MRIReview of systemsGreater frequencyPropensity-score matchingExamination findingsRetrospective studyED readmissionMedical historyHead CTClinical impactMRI examinationsBrain MRINeck CTADizzinessPatientsCost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity
Pryor S, Savoye M, Nowicka P, Price G, Sharifi M, Yaesoubi R. Cost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity. Value In Health 2023, 26: 1183-1191. PMID: 36967028, PMCID: PMC10518029, DOI: 10.1016/j.jval.2023.03.006.Peer-Reviewed Original ResearchConceptsBody mass indexClinical controlMedical Expenditure Panel Survey dataClinical weight managementHealth system perspectivePrevention growth chartsParticipants' body mass indexFamily-based interventionsMass indexChildhood obesityBMI trajectoriesWeight managementHealthcare costsPrimary analysisGrowth chartsObesityTrial dataDisease controlMedical expendituresBright bodiesHealthcare expendituresIncremental costIntervention costsBody interventionsChildrenClinical criteria to exclude acute vascular pathology on CT angiogram in patients with dizziness
Tu L, Malhotra A, Venkatesh A, Taylor R, Sheth K, Yaesoubi R, Forman H, Sureshanand S, Navaratnam D. Clinical criteria to exclude acute vascular pathology on CT angiogram in patients with dizziness. PLOS ONE 2023, 18: e0280752. PMID: 36893103, PMCID: PMC9997874, DOI: 10.1371/journal.pone.0280752.Peer-Reviewed Original ResearchConceptsAcute vascular pathologyEmergency departmentVascular pathologyNegative predictive valueDizzy patientsStroke codeCTA headPredictive valueAdult ED encountersTransient ischemic attackHalf of patientsLong-term smokersLarge vessel occlusionCoronary artery diseasePast medical historySeparate validation cohortCross-sectional analysisIschemic attackAnalysis cohortArterial dissectionArtery diseaseClinical factorsED encountersMedication useChief complaintCost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitionsThe Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018
Li Y, You S, Lee K, Yaesoubi R, Hsu K, Gift T, Chesson H, Berruti A, Salomon J, Rönn M. The Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018. The Journal Of Infectious Diseases 2023, 227: 1007-1018. PMID: 36806950, PMCID: PMC10112678, DOI: 10.1093/infdis/jiad047.Peer-Reviewed Original ResearchConceptsLifetime QALYsSubstantial health lossesDuration of infectionCost-effectiveness analysisGenital chlamydiaInfection interventionTotal QALYsIncident infectionsChronic sequelaeInfection helpGonorrheaAge groupsChlamydiaInfectionMultivariate sensitivity analysisHealth lossTrichomoniasisQALYWomenSequelaeUnited StatesPrevention policiesQALYsPopulation levelLifetime qualityLifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study
You S, Yaesoubi R, Lee K, Li Y, Eppink S, Hsu K, Chesson H, Gift T, Berruti A, Salomon J, Rönn M. Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study. The Lancet Regional Health - Americas 2023, 19: 100427. PMID: 36950038, PMCID: PMC10025423, DOI: 10.1016/j.lana.2023.100427.Peer-Reviewed Original ResearchQuality-adjusted life yearsGenital HSV-1Lifetime quality-adjusted life yearsGenital herpesHSV-2HSV-1Neonatal herpesLife yearsNatural historyLifetime numberNeonatal herpes infectionSubstantial health lossesHealth lossHSV-2 infectionLong-term health impactsHerpes simplex virus type 1Adverse health outcomesDays of lifeSimplex virus type 1Virus type 1Health impactsMollaret's meningitisSacral radiculitisSymptomatic recurrenceUrinary retentionGenerating simple classification rules to predict local surges in COVID-19 hospitalizations
Yaesoubi R, You S, Xi Q, Menzies N, Tuite A, Grad Y, Salomon J. Generating simple classification rules to predict local surges in COVID-19 hospitalizations. Health Care Management Science 2023, 26: 301-312. PMID: 36692583, PMCID: PMC9872755, DOI: 10.1007/s10729-023-09629-4.Peer-Reviewed Original Research
2022
Yield of Head Computed Tomography Examinations for Common Psychiatric Presentations and Implications for Medical Clearance From a 6-Year Analysis of Acute Hospital Visits
Tu LH, Malhotra A, Sheth KN, Yaesoubi R, Forman HP, Venkatesh AK. Yield of Head Computed Tomography Examinations for Common Psychiatric Presentations and Implications for Medical Clearance From a 6-Year Analysis of Acute Hospital Visits. JAMA Internal Medicine 2022, 182: 879-881. PMID: 35727595, PMCID: PMC9214629, DOI: 10.1001/jamainternmed.2022.2198.Peer-Reviewed Original ResearchPredicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods
You S, Chitwood MH, Gunasekera KS, Crudu V, Codreanu A, Ciobanu N, Furin J, Cohen T, Warren JL, Yaesoubi R. Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods. PLOS Digital Health 2022, 1: e0000059. PMID: 36177394, PMCID: PMC9518704, DOI: 10.1371/journal.pdig.0000059.Peer-Reviewed Original ResearchDrug susceptibility testXpert MTB/RIFMachine learning-based modelsLearning-based modelsMachine learning methodsRifampicin-resistant tuberculosisTime of diagnosisRifampin-resistant tuberculosisMTB/RIFNeural network modelLearning methodsNetwork modelMulti-drug resistant tuberculosisNational TB surveillanceDrug-resistant tuberculosisOptimism-corrected areaSelection of antibioticsAnti-TB agentsDistrict-level prevalenceLow-resource settingsPatient characteristicsResistant tuberculosisTB surveillanceAppropriate treatmentDST resultsEstimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018
Lee K, You S, Li Y, Chesson H, Gift TL, Berruti AA, Hsu K, Yaesoubi R, Salomon JA, Rönn M. Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018. Clinical Infectious Diseases 2022, 76: e810-e819. PMID: 35684943, PMCID: PMC9907519, DOI: 10.1093/cid/ciac427.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCongenital syphilisHealth lossLife yearsNumber of QALYsTerms of QALYsLifetime numberBurden of syphilisSubstantial health lossesManagement of syphilisLifetime quality-adjusted life yearsAverage lifetime numberCost-effectiveness analysisPrimary infectionOverall burdenSyphilisNatural historyInfectionHealth impactsMSMChildrenMothersUnited StatesBurdenDecision tree modelEvaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics
Yaesoubi R, Cohen T, Hsu K, Gift TL, St. Cyr SB, Salomon JA, Grad YH. Evaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics. PLOS Computational Biology 2022, 18: e1009842. PMID: 35139073, PMCID: PMC8863219, DOI: 10.1371/journal.pcbi.1009842.Peer-Reviewed Original ResearchConceptsIncidence of gonorrhoeaTreatment guidelinesResistance prevalenceGonorrhea casesTreatment of gonorrheaNational surveillance systemPrevalence of resistanceTransmission dynamic modelGonococcal infectionGonorrhea treatmentMSM populationAntibiotic susceptibilityGonorrheaStandardized guidelinesSurveillance dataPrevalenceIncidenceAntibioticsPotential strategySurveillance systemAbsence of pointsGuidelinesCurrent strategiesEffective lifespanMen